Key result
Non-vitamin K antagonist oral anticoagulants represent a major advancement in deep vein thrombosis management, though drug selection, reversal, and chronic treatment effects remain controversial.
The management of DVT is evolving with the widespread adoption of NOACs and growing interest in early interventional strategies like local thrombolysis, though long-term outcomes require further study.
NOACs advance DVT management yet controversies persist; leaves open optimal selection, reversal strategies, and chronic effects.
In adults diagnosed with deep vein thrombosis (DVT), challenges remain in the management of the acute event whilst remaining alert to long-term morbidity. The addition of non-vitamin K antagonist oral anticoagulants (NOACs) to the pharmacopoeia represents the first of a number of recent advancements in the management of DVT. Worldwide, uptake of these agents has been avid, although drug selection, reversal and chronic treatment effects continue to be controversial areas. Multi-centre studies to evaluate the impact of NOACs on long-term outcomes, including thrombosis recurrence and post-thrombotic syndrome (PTS), are ongoing. Validation of tools capable of predicting PTS would enable patient selection for early aggressive intervention, such as local thrombolysis. Such interventional strategies are gaining momentum as initial approaches and would benefit from large randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2015) conducted a review in Deep vein thrombosis (DVT). Non-vitamin K antagonist oral anticoagulants (NOACs) was evaluated. Non-vitamin K antagonist oral anticoagulants represent a major advancement in deep vein thrombosis management, though drug selection, reversal, and chronic treatment effects remain controversial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: